Benzodiazepines addition to antidepressants increases death risk in depression: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-12-22 14:45 GMT | Update On 2020-12-23 10:05 GMT

Researchers have found in a new research that addition of benzodiazepines to antidepressants monotherapy to treat depression was associated with a moderately increased risk of all-cause mortality when compared to antidepressants monotherapy.

The study has been published in BMC Medicine.

With antidepressants (ADs) having minimal therapeutic effects during the initial weeks of treatment, benzodiazepines (BZDs) are concomitantly used to alleviate depressive symptoms of insomnia or anxiety. However, with mortality risks associated with this concomitant use yet to be examined, it remains unclear as to whether this concomitant therapy offers any benefits in treating depression.

Therefore, Han Eol Jeong and associates from the School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea conducted a population-based cohort study using South Korea's nationwide healthcare database. Of 2.6 million patients with depression, the authors identified 612,729 patients with incident depression and newly prescribed ADs or BZDs, by excluding those with a record of diagnosis or prescription within the 2 years prior to their incident diagnosis.

We classified our study cohort into two discrete groups depending on the type of AD treatment received within 6 months of incident diagnosis—AD monotherapy and AD plus BZD (AD+BZD) therapy describes Jeong.

The researchers matched the study cohort in a 1:1 ratio using propensity scores to balance baseline characteristics and obtain comparability among groups. The primary outcome was all-cause mortality and patients were followed until the earliest outcome occurrence or end of the study period. Multivariable Cox proportional hazards regression analysis was conducted to estimate adjusted hazards ratios (HRs) with 95% confidence intervals (CIs) for the risk of mortality associated with AD+BZD therapy versus AD monotherapy.

The following findings were observed-

a. The propensity score-matched cohort had 519,780 patients with 259,890 patients in each group, where all baseline characteristics were well-balanced between the two groups.

b. Compared to AD monotherapy, AD+BZD therapy was associated with an increased risk of all-cause mortality (adjusted HR, 1.04; 95% CI, 1.02 to 1.06).

Hence, it was concluded that "concomitantly initiating BZDs with ADs was associated with a moderately increased risk of mortality. Clinicians should therefore exercise caution when deciding to co-prescribe BZDs with ADs in treating depression, as associated risks were observed."

Article Source : BMC Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Benzodiazepines addition to antidepressants increases death risk in depression: Study

Similar News

Reformer Pilates Eases Pain and Boosts Well-being in Chronic Pain Patients: Study

Study Shows Poor Sleep Habits May Be Linked to 172 Diseases

Ketamine could treat depression by interacting with the brain's 'opioid system: Study

Higher BMI and Depression Linked to Greater Risk of Urinary Incontinence in Women: NHANES Study

Ibogaine appears to treat traumatic brain injuries in veterans: Study

Exercise Rehab Eases Irregular Heart Rhythm and Improves Mental Health: Study Finds

Ultraprocessed Foods Linked to Increased Parkinson's Disease Risk: Study

Artificial biosensor can better measure the body's main stress hormone: Study